Discovering November 2024's Undiscovered Gems on None Exchange

As global markets show signs of resilience with U.S. indexes approaching record highs and smaller-cap indexes outperforming their larger counterparts, investors are increasingly optimistic amid strong labor market data and stabilizing economic indicators. In this environment, identifying stocks that can capitalize on broad-based gains and sector-specific growth opportunities becomes crucial for those looking to uncover potential gems in the investment landscape.

Top 10 Undiscovered Gems With Strong Fundamentals

Name	Debt To Equity	Revenue Growth	Earnings Growth	Health Rating
Canal Shipping Agencies	NA	8.92%	22.01%	★★★★★★
Zambia Sugar	1.04%	20.60%	44.34%	★★★★★★
Suez Canal Company for Technology Settling (S.A.E)	NA	22.31%	13.60%	★★★★★★
Impellam Group	31.12%	-5.43%	-6.86%	★★★★★★
Ovostar Union	0.01%	10.19%	49.85%	★★★★★★
La Forestière Equatoriale	NA	-58.49%	45.78%	★★★★★★
Tianyun International Holdings	10.09%	-5.59%	-9.92%	★★★★★★
Infinity Capital Investments	NA	9.92%	22.16%	★★★★★☆
Wilson	64.79%	30.09%	68.29%	★★★★☆☆
A2B Australia	15.83%	-7.78%	25.44%	★★★★☆☆

Click here to see the full list of 4638 stocks from our Undiscovered Gems With Strong Fundamentals screener.

Here we highlight a subset of our preferred stocks from the screener.

Wavestone (ENXTPA:WAVE)

Simply Wall St Value Rating: ★★★★★★

Overview: Wavestone SA is a consulting firm offering management and information system services both in France and internationally, with a market capitalization of approximately €1.12 billion.

Operations: Wavestone generates revenue primarily from its management consulting and information system services, amounting to €701.06 million.

Wavestone stands out with its high-quality earnings and impressive growth trajectory. Over the past year, its earnings surged by 16.2%, outpacing the IT industry's -5.6% performance, suggesting robust operational strength. The company is trading at a significant discount of 30.5% below its estimated fair value, presenting a potential opportunity for investors seeking undervalued assets in the sector. Additionally, Wavestone's debt to equity ratio has impressively decreased from 58.5% to 10.2% over five years, indicating strong financial management and reduced leverage risk while maintaining positive free cash flow throughout this period.

• Get an in-depth perspective on Wavestone's performance by reading our health report here.

• Examine Wavestone's past performance report to understand how it has performed in the past.

Guangdong VTR Bio-Tech (SZSE:300381)

Simply Wall St Value Rating: ★★★★★☆

Overview: Guangdong VTR Bio-Tech Co., Ltd. is engaged in the research, development, production, sale, and servicing of biological enzyme preparations, biosynthetics, and nutrition and health products in China with a market cap of CN¥3.69 billion.

Operations: Guangdong VTR Bio-Tech generates revenue primarily through the sale of biological enzyme preparations, biosynthetics, and nutrition and health products. The company focuses on optimizing its cost structure to enhance profitability. Notably, it has experienced variations in its gross profit margin over recent periods.

Guangdong VTR Bio-Tech, a company with a focus on biotechnology, has shown impressive earnings growth of 395.6% over the past year, significantly outpacing the industry average of 0.08%. The firm reported net income for the first nine months of 2024 at CN¥42.8 million, up from CN¥12.39 million in the previous year, with basic earnings per share rising to CN¥0.0873 from CN¥0.0253. Despite this growth spurt, it's worth noting that a substantial one-off gain of CN¥30.5 million impacted its financial results recently, and their debt-to-equity ratio notably decreased from 44.6% to just 3.4% over five years—indicative of improved financial health and reduced leverage risks moving forward.

• Delve into the full analysis health report here for a deeper understanding of Guangdong VTR Bio-Tech.

• Gain insights into Guangdong VTR Bio-Tech's past trends and performance with our Past report.

Shenzhen Bestek Technology (SZSE:300822)

Simply Wall St Value Rating: ★★★★★★

Overview: Shenzhen Bestek Technology Co., Ltd. focuses on the research and development, manufacture, and sale of smart controllers and products both in China and internationally, with a market cap of CN¥7.49 billion.

Operations: Shenzhen Bestek Technology generates revenue primarily from the sale of smart controllers and related products. The company's gross profit margin has shown variability, reflecting changes in production costs and pricing strategies.

Shenzhen Bestek Technology has caught attention with its impressive earnings growth of 213.5% over the past year, outpacing the Electrical industry’s modest 1.1%. Despite a history of earnings decline by 31.3% annually over five years, recent performance shows promise with net income rising to CNY 59.65 million from CNY 38.64 million a year earlier, and basic EPS improving to CNY 0.1915 from CNY 0.124. The company operates debt-free and enjoys positive free cash flow, suggesting financial stability amidst its volatile share price in recent months, positioning it as an intriguing player for potential investors seeking growth opportunities in this sector.

• Unlock comprehensive insights into our analysis of Shenzhen Bestek Technology stock in this health report.

• Learn about Shenzhen Bestek Technology's historical performance.

Summing It All Up

• Unlock our comprehensive list of 4638 Undiscovered Gems With Strong Fundamentals by clicking here.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com